CSL Behring launches next generation HeliTrax System for Apple's devices

CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple's iPhone®, iPod touch®, or iPad™ devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII).

The new HeliTrax software is designed with an interface that ensures compatibility with both Lab Tracker™ and WebTracker™ patient management systems used by hemophilia treatment centers throughout the U.S. This software automatically transmits patient information to the hemophilia treatment centers, making disorder management easier for both users and staff. The interface was built in collaboration with the American Thrombosis and Hemostasis Network (ATHN).  ATHN is a nonprofit organization founded to advance and improve the care of individuals affected by bleeding and thrombotic disorders.

"CSL Behring continually strives to enhance the quality of our services based on what we know people and their treatment providers need and want," said Garrett E. Bergman, MD, Senior Director of Medical Affairs, North America Commercial Operations at CSL Behring. "The advancement of patient management is a priority that we share with hemophilia treatment centers. Our updates to HeliTrax will help meet that goal by improving data management and ease of user-provider communications."

The HeliTrax system is now available through CSL Behring on an iPhone as well as via download through Apple's App Store(SM). The new platform for HeliTrax aims to improve the user experience, while providing the opportunity for scalability and future enhancements.

Healthcare providers monitoring people with hemophilia A often rely on paper forms filled out by patients or their caregivers to obtain a clear overview of the condition. However, the forms do not always provide necessary clinical information in a timely, clear and concise way.

"I used to fill out paper logs to help my six sons manage their hemophilia A, but once I tried HeliTrax, I knew I'd never go back," said Erica Boone of Sedalia, Missouri.  "HeliTrax keeps all information related to my sons' condition in one place, making it easy to stay organized and communicate with their treatment team."

HeliTrax, launched by CSL Behring in 2008, tracks user treatment as it happens — including medication usage and inventory — and now automatically syncs the data to the treatment center's Lab Tracker and WebTracker systems, eliminating the need for treatment center staff to manually re-enter it. The software and auto syncing feature help reduce documentation and transcription errors, and the system is compliant with the Joint Commission and the Health Insurance Portability and Accountability Act (HIPAA).  CSL Behring preserves patient privacy and confidentiality, and has no access to data collected by the HeliTrax System. All data is collected, stored, and managed by an independent third-party organization.

"We are pleased that CSL Behring has made it possible for users of the HeliTrax System to share their bleed and infusion information electronically with their treatment centers, and importantly, interface directly with the WebTracker™ patient management system," said Diane Aschman, President and CEO of the American Thrombosis and Hemostasis Network (ATHN). "ATHN has partnered with treatment centers across the U.S. to create one national database for the bleeding disorders community and we believe that patient self-reported data about bleeds and infusions using a user-friendly electronic system that is integrated into our national infrastructure, will lead to a better understanding and management of these disorders, as well as the development of more research and treatment options." 

For more information about HeliTrax, please visit www.ConnectwithHelitrax.com.